Skip to content

Latest

Rite Aid introduces drug disposal units

Rite Aid introduces drug disposal units

Rite Aid Corp. last month unveiled the company’s first in-store medication disposal unit at the Rite Aid pharmacy in Lemoyne, Pa., as part of its overall strategy of combating drug abuse. Rite Aid plans to install 100 medication disposal units in selected pharmacies over the next year.

CVS rolls out delivery service

CVS rolls out delivery service

CVS Pharmacy has expanded its prescription delivery service nationwide and made same-day delivery available in five new major markets. The move makes CVS the first national retailer to make both pharmacy and front-end delivery available chainwide.

New Voices Fund rolls out during 2018 Essence Festival

New Voices Fund rolls out during 2018 Essence Festival

NEW YORK – The $100 million New Voices Fund, the next-generation fund set up to make private equity investments in businesses owned and/or managed by women of color, officially launched today at the 2018 Essence Festival in New Orleans.

WBA finalizes investment in pharmacy chain GuoDa

WBA finalizes investment in pharmacy chain GuoDa

DEERFIELD, Ill. – Walgreens Boots Alliance (WBA) today announced that, following receipt of regulatory approvals, it has completed the previously announced agreement to acquire a 40% minority stake in Sinopharm Holding GuoDa Drugstores Co., Ltd. (GuoDa), a leading retail pharmacy chain in China.

Catalent agrees to buy Juniper Pharmaceuticals

Catalent agrees to buy Juniper Pharmaceuticals

SOMERSET, N.J. – Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products,  announced that it has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, U.K.-based Juniper Pharma Services division.

FDA approves Xeomin for adult patients with sialorrhea

FDA approves Xeomin for adult patients with sialorrhea

Merz North America announced  that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients.